Standardized total average toxicity score: A scale- and grade-independent measure of late radiotherapy toxicity to facilitate pooling of data from different studies

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 3, 2012, Pages 1065-1074

  Barnett, Gillian C ^a,b   West, Catharine M L ^c   Coles, Charlotte E ^a   Pharoah, Paul D P ^b   Talbot, Christopher J ^d   Elliott, Rebecca M ^c   Tanteles, George A ^e   Symonds, R Paul ^e   Wilkinson, Jennifer S ^a   Dunning, Alison M ^b   Burnet, Neil G ^a   Bentzen, Søren M ^f  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Adverse effects; Breast cancer; Late toxicity; Radiotherapy; Statistics

Indexed keywords

ACUTE TOXICITY; ADVERSE EFFECT; BREAST CANCER; CAMBRIDGE; COSMESIS; COVARIATES; DATA SETS; INTENSITY-MODULATED RADIOTHERAPY; MISSING DATA; RADIATION TOXICITY; SCORING SYSTEMS; SURGICAL SPECIMENS; TUMOR BED;

CHEMOTHERAPY; RADIOTHERAPY; SEARCH ENGINES; STATISTICS; SURGERY;

TOXICITY;

ACUTE TOXICITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DOSIMETRY; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MEASUREMENT; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RADIATION INJURY; RATING SCALE; SCORING SYSTEM; SENSITIVITY ANALYSIS; SMOKING; STANDARDIZED TOTAL AVERAGE TOXICITY SCORE;

AGE FACTORS; ALGORITHMS; ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; DIABETES MELLITUS; FEMALE; HUMANS; ORGAN SIZE; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SMOKING; TUMOR BURDEN;

EID: 84856395883     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.03.015     Document Type: Article

References (40)

1. A. Trotti, and S.M. Bentzen The need for adverse effects reporting standards in oncology clinical trials J Clin Oncol 22 2004 19 22
2. Bentzen SM, Constine LS, Deasy JO, et al. Quantitative analyses of normal tissue effects in the clinic (QUANTEC): An introduction to the scientific issues. Int J Radiat Oncol Biol Phys;76:S3-S9.
3. A. Jackson, L.B. Marks, and S.M. Bentzen The lessons of QUANTEC: Recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome Int J Radiat Oncol Biol Phys 76 2010 S155 S160
4. J.O. Deasy, S.M. Bentzen, and A. Jackson Improving normal tissue complication probability models: The need to adopt a "data-pooling" culture Int J Radiat Oncol Biol Phys 76 2010 S151 S154
5. G.C. Barnett, C.M. West, and A.M. Dunning Normal tissue reactions to radiotherapy: Towards tailoring treatment dose by genotype Nat Rev Cancer 9 2009 134 142
6. S.M. Bentzen Preventing or reducing late side effects of radiation therapy: Radiobiology meets molecular pathology Nat Rev Cancer 6 2006 702 713
7. C. West, B.S. Rosenstein, and J. Alsner Establishment of a radiogenomics consortium Int J Radiat Oncol Biol Phys 76 2010 1295 1296
8. A. Trotti, A.D. Colevas, and A. Setser CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 2003 176 181
9. Lent SOMA scales for all anatomic sites Int J Radiat Oncol Biol Phys 31 1995 1049 1091
10. S.M. Bentzen, R.K. Agrawal, and E.G. Aird The UK standardisation of breast radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial Lancet 371 2008 1098 1107
11. S.M. Bentzen, R.K. Agrawal, and E.G. Aird The UK standardisation of breast radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial Lancet Oncol 9 2008 331 341
12. S.M. Bentzen, and J. Overgaard Patient-to-patient variability in the expression of radiation-induced normal tissue injury Semin Radiat Oncol 4 1994 68 80
13. C. Lilla, C.B. Ambrosone, and S. Kropp Predictive factors for late normal tissue complications following radiotherapy for breast cancer Breast Cancer Res Treat 106 2007 143 150
14. Barnett GC, Wilkinson JC, Moody AM, et al. The Cambridge breast IMRT trial: Patient and treatment-related risk factors for the development of normal tissue toxicity. Clin Oncol. In press.
15. G.C. Barnett, J.S. Wilkinson, and A.M. Moody Randomized controlled trial of forward-planned intensity-modulated radiotherapy for early breast cancer: Interim results at 2 years Int J Radiat Oncol Biol Phys. 2011 Feb 22. [Epub ahead of print]
16. G. Giotopoulos, C. Armstrong, and A. Osman Refining the evidence for GSTA1 and eNOS genetic effects on risk of radiotherapy-induced telangiectasia Int J Cancer 123 2008 2973 2974
17. G. Giotopoulos, R.P. Symonds, and K. Foweraker The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes Br J Cancer 96 2007 1001 1007
18. G.A. Tanteles, J. Whitworth, and J. Mills Can cutaneous telangiectasiae as late normal-tissue injury predict cardiovascular disease in women receiving radiotherapy for breast cancer? Br J Cancer 101 2009 403 409
19. I. Turesson, J. Nyman, and E. Holmberg Prognostic factors for acute and late skin reactions in radiotherapy patients Int J Radiat Oncol Biol Phys 36 1996 1065 1075
20. C.N. Andreassen, and J. Alsner Genetic variants and normal tissue toxicity after radiotherapy: A systematic review Radiother Oncol 92 2009 299 309
21. N.G. Burnet, R. Wurm, and J. Nyman Normal tissue radiosensitivity: How important is it? Clin Oncol (R Coll Radiol) 8 1996 25 34
22. C.M. West, R.M. Elliott, and N.G. Burnet The genomics revolution and radiotherapy Clin Oncol (R Coll Radiol) 19 2007 470 480
23. C. West, and B.S. Rosenstein Establishment of a radiogenomics consortium Radiother Oncol 94 2010 117 118
24. P.M. Poortmans, L. Collette, and H. Bartelink The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer: A summary of the results of EORTC 22881-10882 "boost versus no boost" trial Cancer Radiother 12 2008 565 570
25. P. Romestaing, Y. Lehingue, and C. Carrie Role of a 10-Gy boost in the conservative treatment of early breast cancer: Results of a randomized clinical trial in Lyon, France J Clin Oncol 15 1997 963 968
26. J.P. Pignol, I. Olivotto, and E. Rakovitch A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis J Clin Oncol 26 2008 2085 2092
27. D. Twardella, O. Popanda, and I. Helmbold Personal characteristics, therapy modalities and individual DNA repair capacity as predictive factors of acute skin toxicity in an unselected cohort of breast cancer patients receiving radiotherapy Radiother Oncol 69 2003 145 153
28. M. Back, M. Guerrieri, and C. Wratten Impact of radiation therapy on acute toxicity in breast conservation therapy for early breast cancer Clin Oncol (R Coll Radiol) 16 2004 12 16
29. S.M. Bentzen, and M. Overgaard Relationship between early and late normal-tissue injury after postmastectomy radiotherapy Radiother Oncol 20 1991 159 165
30. S.M. Bentzen, M. Overgaard, and J. Overgaard Clinical correlations between late normal tissue endpoints after radiotherapy: Implications for predictive assays of radiosensitivity Eur J Cancer 29A 1993 1373 1376
31. P.J. Eifel, A. Jhingran, and D.C. Bodurka Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer J Clin Oncol 20 2002 3651 3657
32. J.C. van der Voet, R.B. Keus, and A.A. Hart The impact of treatment time and smoking on local control and complications in T1 glottic cancer Int J Radiat Oncol Biol Phys 42 1998 247 255
33. T. Rugg, M.I. Saunders, and S. Dische Smoking and mucosal reactions to radiotherapy Br J Radiol 63 1990 554 556
34. B.H. Chon, and J.S. Loeffler The effect of nonmalignant systemic disease on tolerance to radiation therapy Oncologist 7 2002 136 143
35. S.J. Bowden, I.N. Fernando, and A. Burton Delaying radiotherapy for the delivery of adjuvant chemotherapy in the combined modality treatment of early breast cancer: Is it disadvantageous and could combined treatment be the answer? Clin Oncol (R Coll Radiol) 18 2006 247 256
36. S. Collette, L. Collette, and T. Budiharto Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: A study based on the EORTC Trial 22881-10882 'boost versus no boost.' Eur J Cancer 44 2008 2587 2599
37. J. Denekamp, H. Bartelink, and P. Rubin Correction for the use of the SOMA LENT tables. American and European LENT Working Committees Radiother Oncol 39 1996 191
38. J. Denekamp, H. Bartelink, and P. Rubin Correction for the use of the SOMA LENT tables Int J Radiat Oncol Biol Phys 35 1996 417
39. Y. Anacak, D. Yalman, and Z. Ozsaran Late radiation effects to the rectum and bladder in gynecologic cancer patients: the comparison of LENT/SOMA and RTOG/EORTC late-effects scoring systems Int J Radiat Oncol, Biol, Phys 50 2001 1107 1112
40. S.E. Davidson, M.P. Burns, and J.A. Routledge Assessment of morbidity in carcinoma of the cervix: A comparison of the LENT SOMA scales and the Franco-Italian glossary Radiother Oncol 69 2003 195 200